Biotech Stock Still 700%: What Investors Should Do Today
A biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
Choosing the right passive funds can reduce costs and improve retirement outcomes. Explore Which Passive Funds Are Best Value For Retirement to find efficient options.
26,439 articlesA biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
Developers shift from splashy amenities to intentional spaces that foster belonging, a move that also redefines how l...
Investors are weighing a shift from high-growth tech to more income-driven energy plays as AI-era capex creates uncer...
ClearPoint’s early-2026 earnings signal a busy year ahead. This analysis breaks down revenue, margins, guidance, and ...
Boot Barn stands at a crossroads in 2026. This guide breaks down the growth drivers, potential risks, and practical i...
When a notable manager trims a stake in a popular ETF, it can offer clues about risk, opportunity, and the broader ma...
Anthropic’s dispute with the Pentagon over ethical uses triggers a contract cancellation and a supply chain risk desi...
A fresh stake of roughly $4.5 million by a value-focused firm in Workiva raises questions about what comes next for W...
Novo Nordisk has faced headwinds, but a new GLP-1 drug could change the game. This article breaks down what investors...
Palantir maintains AI-driven momentum into 2026, but investors weigh continued growth against contracts and policy ri...
OpenAI’s fresh developments could tilt the landscape for AI hardware suppliers. This guide explains what Broadcom sto...
A major adviser boosted its stake in Savara by more than a million shares during the latest quarter, wading into a bi...